Displaying publications 1 - 20 of 35 in total

Abstract:
Sort:
  1. Thayaparan A
    Family Practitioner, 1984;7(1):12-13.
    Matched MeSH terms: Rheumatology
  2. Sachdev Manjit Singh B, Chuah SL, Cheong YK, Wan SA, Teh CL
    Ann Rheum Dis, 2023 Feb;82(2):e39.
    PMID: 32769156 DOI: 10.1136/annrheumdis-2020-218484
    Matched MeSH terms: Rheumatology*
  3. Yeap SS, Veerapen K, Lim KKT
    DOI: 10.1111/j.1479-8077.2005.00157.x
    Matched MeSH terms: Rheumatology
  4. Teng CL, Chew WZ, Das Gupta E, Yeap SS
    Clin Rheumatol, 2020 Feb;39(2):547-552.
    PMID: 31784864 DOI: 10.1007/s10067-019-04839-0
    OBJECTIVES: To assess the content, authorship and study design of rheumatological publications written by Malaysian authors or about rheumatological conditions in Malaysia.

    METHODS: The Malaysian Medical Repository (MyMedR), a web-based database of Malaysian health and medical publications, and Scopus were searched to retrieve rheumatological publications from Malaysia, for the period 1950 until 30 June 2019. The type and number of publications in each rheumatological subject area and the overall trend of publication numbers and citations were analysed.

    RESULTS: 547 publications were found for the time period studied. There was a 27-fold increase in the number of publications from the period up to 1980 compared to 2010-2019. The median number of citations per paper was 5, but unlike the number of publications, there was only a slight increase in the number of citations with time. 84.5% of the papers were cited at least once. The top 3 conditions generating the most publications were systemic lupus erythematosus, 36.7%, followed by rheumatoid arthritis, 17.0%, and osteoporosis, 13.9%.

    CONCLUSIONS: The number of rheumatological publications in Malaysia have increased over time, especially in the last decade. However, the average number of citations per publications remains low and the majority of publications are in journals with low impact factors. Thus, the quality of rheumatological publications from Malaysia can be further improved.Key Points• There have been only a limited number of bibliometric analysis of rheumatology publications from Asia.• In Malaysia, the number of rheumatology publications has increased over time.• However, there is still room for improvement in terms of the quality of the publications.

    Matched MeSH terms: Rheumatology*
  5. Chapter of Rheumatologists, Singapore Society of Rheumatology, Chapter of Infectious Disease Physicians, Society of Infectious Disease Singapore
    Singapore Med J, 2016 Feb;57(2):98-100.
    PMID: 27326437
    Matched MeSH terms: Rheumatology/history*
  6. Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, et al.
    RMD Open, 2022 Apr;8(1).
    PMID: 35387864 DOI: 10.1136/rmdopen-2021-002187
    OBJECTIVE: While COVID-19 vaccination prevents severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analysed the clinical characteristics of patients with rheumatic disease who developed breakthrough COVID-19 after vaccination against SARS-CoV-2.

    METHODS: We included people partially or fully vaccinated against SARS-CoV-2 who developed COVID-19 between 5 January and 30 September 2021 and were reported to the Global Rheumatology Alliance registry. Breakthrough infections were defined as occurring ≥14 days after completion of the vaccination series, specifically 14 days after the second dose in a two-dose series or 14 days after a single-dose vaccine. We analysed patients' demographic and clinical characteristics and COVID-19 symptoms and outcomes.

    RESULTS: SARS-CoV-2 infection was reported in 197 partially or fully vaccinated people with rheumatic disease (mean age 54 years, 77% female, 56% white). The majority (n=140/197, 71%) received messenger RNA vaccines. Among the fully vaccinated (n=87), infection occurred a mean of 112 (±60) days after the second vaccine dose. Among those fully vaccinated and hospitalised (n=22, age range 36-83 years), nine had used B cell-depleting therapy (BCDT), with six as monotherapy, at the time of vaccination. Three were on mycophenolate. The majority (n=14/22, 64%) were not taking systemic glucocorticoids. Eight patients had pre-existing lung disease and five patients died.

    CONCLUSION: More than half of fully vaccinated individuals with breakthrough infections requiring hospitalisation were on BCDT or mycophenolate. Further risk mitigation strategies are likely needed to protect this selected high-risk population.

    Matched MeSH terms: Rheumatology*
  7. Clinical Practice Guidelines: Management of Osteoporosis, Second Edition. Putrajaya: Ministry of Health, Malaysia; 2015

    Older versions:
    Clinical Practice Guidelines: Management of Osteoporosis. Kuala Lumpur: Malaysian Osteoporosis Society, Malaysia; 2001
    Clinical Practice Guidelines: Management of Osteoporosis, Kuala Lumpur: Malaysian Osteoporosis Society, Malaysia; 2006
    Clinical Practice Guidelines: Management of Osteoporosis, First Edition. Putrajaya: Ministry of Health, Malaysia; 2012
    Keywords: CPG
    Matched MeSH terms: Rheumatology
  8. Clinical Practice Guidelines: Management of Gout. Putrajaya: Ministry of Health, Malaysia; 2008

    Keywords: CPG
    Matched MeSH terms: Rheumatology
  9. Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM, et al.
    Int J Rheum Dis, 2015 Sep;18(7):685-713.
    PMID: 26334449 DOI: 10.1111/1756-185X.12754
    Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia-Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue.
    Matched MeSH terms: Rheumatology/standards*
  10. Mok TM
    Int J Rheum Dis, 2015 Jun;18(5):583-6.
    PMID: 26082351 DOI: 10.1111/1756-185X.12676
    Matched MeSH terms: Rheumatology*
  11. Arshad A, Kong KO
    Singapore Med J, 2007 Jan;48(1):25-30.
    PMID: 17245512
    INTRODUCTION: Fibromyalgia syndrome (FMS) is a common but controversial condition. There appears to be different levels of belief of its existence and awareness. We set out to explore the variations of perceptions and awareness of this condition among rheumatologists from Malaysia and Singapore.
    METHODS: 48 rheumatologists from Malaysia (28) and Singapore (20) were approached to participate in this survey by answering a specific questionnaire regarding their belief in FMS. 23 respondents from Malaysia and 20 from Singapore completed the questionnaire.
    RESULTS: 91 percent of Malaysian rheumatologists and 95 percent of the Singaporean believe that FMS is a distinct clinical entity and that this condition is considered an illness rather than a disease. 87 percent and 90 percent of rheumatologists from Malaysia and Singapore, respectively, believe that FMS is a mixture of medical and psychological illness. However, not many of those in the university setting include FMS in their undergraduate teaching. 87 percent and 80 percent of the respondents from Malaysia and Singapore, respectively, also ordered blood tests to exclude other serious pathologies, and 100 percent of the respondents from both countries also prescribed some form of drugs to their FMS patients.
    CONCLUSION: This study confirmed that there was a variation of perceptions and knowledge of FMS among rheumatologists from Malaysia and Singapore. The majority of rheumatologists recognise that FMS is a distinct clinical entity, and is diagnosed by excluding other well-defined clinical diseases through a combination of clinical evaluation and screening tests.
    Matched MeSH terms: Rheumatology*
  12. Al Maini M, Al Weshahi Y, Foster HE, Chehade MJ, Gabriel SE, Saleh JA, et al.
    Clin Rheumatol, 2020 Mar;39(3):627-642.
    PMID: 31127461 DOI: 10.1007/s10067-019-04544-y
    Rheumatic and musculoskeletal diseases (RMDs) encompass a spectrum of degenerative, inflammatory conditions predominantly affecting the joints. They are a leading cause of disability worldwide and an enormous socioeconomic burden. However, worldwide deficiencies in adult and paediatric RMD knowledge among medical school graduates and primary care physicians (PCPs) persist. In October 2017, the World Forum on Rheumatic and Musculoskeletal Diseases (WFRMD), an international think tank of RMD and related experts, met to discuss key challenges and opportunities in undergraduate RMD education. Topics included needs analysis, curriculum content, interprofessional education, teaching and learning methods, implementation, assessment and course evaluation and professional formation/career development, which formed a framework for this white paper. We highlight a need for all medical graduates to attain a basic level of RMD knowledge and competency to enable them to confidently diagnose, treat/manage or refer patients. The importance of attracting more medical students to a career in rheumatology, and the indisputable value of integrated, multidisciplinary and multiprofessional care are also discussed. We conclude that RMD teaching for the future will need to address what is being taught, but also where, why and to whom, to ensure that healthcare providers deliver the best patient care possible in their local setting.
    Matched MeSH terms: Rheumatology/education*; Rheumatology/methods
  13. Das Gupta E, Goh EM, Gun SC, Hussein H, Shahril NS, Yeap SS, et al.
    EXCLI J, 2013;12:521-2.
    PMID: 27034635
    Matched MeSH terms: Rheumatology
  14. Arshad A, Kong KO
    J Clin Rheumatol, 2007 Apr;13(2):59-62.
    PMID: 17414529 DOI: 10.1097/01.rhu.0000260494.29921.9e
    BACKGROUND: Fibromyalgia syndrome (FMS) is a common but controversial condition. There appears to be different level of belief of its existence and awareness. We set out to explore the variations of perceptions and awareness of this condition among rheumatologists from the Southeast Asia (SEA) region.
    METHODS: One hundred eight rheumatologists from the participating countries; 28 from Malaysia, 20 from Singapore, 26 from Thailand, 2 from Brunei, and 42 from Indonesia were approached to participate in this survey by answering specific questions regarding their beliefs in relation to FMS; 82% respondents from Malaysia, 100% from Singapore, 92% from Thailand, 100% from Brunei, and 90% from Indonesia completed the questionnaires.
    RESULTS: Most rheumatologists (92.5%) from SEA believe that FMS is a distinct clinical entity, and also this condition is considered an illness rather than a disease. Eighty-seven percent rheumatologists from SEA believe that FMS is a mixture of medical and psychological illness, 9% believe that FMS is primarily a psychological illness, and 3% believe that it is a medical illness. Only 60% of those in a university setting include FMS in their undergraduate teaching. Eighty-five percent of the respondents ordered blood tests to exclude other serious pathologic conditions, and 100% of the respondents from SEA countries also prescribed some form of drugs to FMS patients.
    CONCLUSION: FMS is apparently seen worldwide. This study confirmed that there was a variation of perceptions and knowledge of FMS among rheumatologists from SEA countries. However, most rheumatologists agreed that FMS is a distinct clinical entity with a mixture of medical and psychological factors.
    Matched MeSH terms: Rheumatology/standards*
  15. Yeap SS, Gun SC
    Ann Rheum Dis, 2013 May;72(5):e5.
    PMID: 23328940 DOI: 10.1136/annrheumdis-2012-203161
    Comment on: Doherty M, Jansen TL, Nuki G, et al. Gout: Why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765–70.
    Matched MeSH terms: Rheumatology*
  16. Foster HE, Scott C
    Nat Rev Rheumatol, 2020 03;16(3):123.
    PMID: 31932748 DOI: 10.1038/s41584-020-0368-6
    Matched MeSH terms: Rheumatology/trends*
  17. Abdul Satar NF, Cheong EV, Jasmin LPY, Ngu MR
    Med J Malaysia, 2020 11;75(6):738-741.
    PMID: 33219188
    Cancer during pregnancy is a rare condition. We report here a case of a lady diagnosed with nasopharyngeal carcinoma (NPC) at University of Malaya Medical Centre during her first pregnancy conceived via In Vitro Fertilisation (IVF). A multidisciplinary (MDT) meeting among Oncology, Obstetrics, Rheumatology and Otolaryngology teams was conducted to discuss her treatment options. She opted for treatment with Complementary and Alternative Medicine (CAM). This case illustrates the unique challenges in the oncological management of a patient diagnosed with NPC during pregnancy. It also serves as a reminder that the use of CAM in cancer patients is prevalent. It is important for doctors to inquire about use of CAM and to be well-informed about it. Transparent communication and taking cognizance of the goals and concerns of the patients are essential in delivering patient-centred care.
    Matched MeSH terms: Rheumatology
  18. Ong SG, Ding HJ
    Malays Fam Physician, 2021 Mar 25;16(1):50-55.
    PMID: 33948142 DOI: 10.51866/oa0892
    Introduction: The purpose of this study was to describe the local experience in terms of drug efficacy and safety using a new xanthine oxidase inhibitor, febuxostat, as a second-line urate-lowering therapy (ULT) in gout patients with normal renal function and chronic kidney disease.

    Methods: This cross-sectional study included all gout patients who attended the rheumatology clinic from January 2013 to June 2018 and had received febuxostat as a second-line ULT. Analysis focused on the proportion of gout patients who achieved target serum urate (sUA) of <360 μmol/L, duration taken to achieve target sUA, and febuxostat dosage at achievement of target sUA. Safety assessments included comparison of serum creatinine, estimated glomerular filtration rate (eGFR), and serum alanine aminotransferase (ALT) at baseline, at achievement of target sUA, and at 12-monthly intervals.

    Results: Majority (90.9%) of patients achieved target sUA. Median duration required to achieve target sUA was 5.5 months with IQR (interquartile range) of 8.5. Five (22.7%) patients achieved target sUA within one month of therapy with febuxostat 40 mg per day. Eleven (55%) patients achieved target sUA within six months and 16 (80%) by 12 months. Equal proportion of patients achieved target sUA with febuxostat 40 mg per day and 80 mg per day, respectively. There was no significant difference in the changes in serum creatinine level, eGFR and ALT from baseline and at achievement of target sUA, nor at 12-monthly intervals throughout the duration of febuxostat therapy. Apart from three patients who developed hypersensitivity reactions to febuxostat, no other adverse events were reported.

    Conclusion: A significant proportion of gout patients with CKD managed to achieve target sUA with a lower dose of febuxostat at 40 mg per day and it is reasonable to maintain this dose for up to six months before considering dose escalation.

    Matched MeSH terms: Rheumatology
  19. Chai WL, Phang YH, Chong HC
    MyJurnal
    Tumoral calcinosis is an uncommon condition which has been described to exist in primary and secondary forms. A lack of awareness of this entity can lead to unnecessary procedures and incorrect management. We report a case of a patient on peritoneal dialysis who presented with multiple painful joint swellings to the orthopaedic department. An initial diagnosis of septic arthritis was made, then revised to chronic tophaceous gout and referred to the rheumatology unit.
    Matched MeSH terms: Rheumatology
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links